Gout drug success for Novartis
Friday, May 27, 2011
Gout drug success for Novartis
Gout drug success for Novartis
Monday, May 9, 2011
Pfizer RA Drug Meets Study Goals
Saturday, April 30, 2011
Top-line results from Pfizer's tofacitinib Phase 3 studies in RA
Thursday, August 26, 2010
FDA approves Chelsea Therapeutics' Phase II protocol for CH-4051 antifolate in rheumatoid arthritis
"Although MTX is considered the standard of care in RA, both as a monotherapy and in combination with other RA treatments, the dosing and maximal therapeutic benefit of MTX is limited by well-documented tolerability issues, long-term safety concerns and variable bioavailability," commented Dr. Simon Pedder, president and CEO of Chelsea Therapeutics. "Given that CH-4051 is metabolically stable and that all of our preclinical and clinical work suggests enhanced absorption, dramatically increased potency and improved tolerability over MTX, we believe CH-4051 will be safe and highly efficacious in a historically treatment-resistant patient population."
Saturday, May 8, 2010
Vinpocetine from the periwinkle plant, as a potent anti-inflammatory agent....
"Given vinpocetine's efficacy and solid safety profile, we believe there is great potential to bring this drug to market." claims co-author, Dr. Bradford C. Berk...
Inflammatory diseases are a major cause of illness worldwide. For example, chronic obstructive pulmonary disease is the fourth leading cause of death in the United States. In people with COPD, airflow is blocked due to chronic bronchitis or emphysema, making it increasingly difficult to breathe. Most COPD is caused by long-term smoking, although genetics may play a role as well.....
Ref : http://www.urmc.rochester.edu/news/story/index.cfm?id=2836
Monday, April 26, 2010
MIF (Macrophage migration Inhibitory Factor) - a new molecular target for the treatment of depressant and anxiety...
Sunday, April 11, 2010
Minocycline - Effective defense against HIV ?
Wednesday, March 17, 2010
Salsalate may be useful for the treatment of patients with type 2 diabetes .....
Now researchers from Harvard Medical School, lead by Dr. Allison Goldfine, have come up with interesting finding, i.e., Salsalate may be useful for the treatment of patients with type 2 diabetes as well. In a three-month trial of people with type 2 diabetes , those who took the drug showed significantly improved blood glucose levels.
Sunday, February 28, 2010
Serotonin-Specific Reuptake Inhibitor (SSRIs) as antiinflammatory agents?
Researchers observed reduced inflammation, reduced cartilage and bone erosion, and a preservation of the joint structure in the mice treated with a higher dose of fluoxetine. Citalopram was not as effective as fluoxetine at inhibiting disease progression in this model.
Tuesday, January 12, 2010
Celecoxib reduces the risk of common skin cancer in humans.....
For the current research, Tang and her colleagues capitalized on a previous finding suggesting that celecoxib, a NSAID, can inhibit the development of a different kind of skin cancer, squamous cell carcinoma, in mice. They wondered if the drug, sold by the pharmaceutical company Pfizer under the brand names Celebrex and Onsenal, would have a similar effect on the more common basal cell carcinoma.
Celecoxib is thought to work to prevent or slow cancer growth by interfering with the action of an enzyme called Cox-2, which causes tissue inflammation (pro inflammator). Celecoxib has both pain-killing (analgesic) and anti-inflammatory properties. Chronic inflammation has long been associated with the development of many types of cancer, and celecoxib has been shown in clinical trials to reduce the incidence of colon cancer in people with a genetic predisposition to the disease.
Interestingly, researchers stopped the clinical trials in 2003 (from 2001) when the study lead to high risk of heart attack and stroke in patients taking a different NSAID. (Rofecoxib, Vioxx by Merck & Co. was withdrawn from the market by Merck in 2004 and Tang's trial was discontinued that year in response to ongoing concerns about long-term treatment with Cox-2 inhibitors). At that time, most participants had received about two years of drug treatment. No patient died or suffered adverse cardiovascular events due to their participation in the trial. Although drug treatment had been discontinued, the researchers continued to monitor basal cell carcinoma formation in people who had received the drug or placebo for an additional year to complete the three-year study. They found that, although both groups continued to develop new cancers during the study, oral celecoxib treatment decreased the growth of skin tumors by about 50 percent as compared to placebo in participants who entered the trial with 15 or fewer basal cell carcinomas. Celecoxib treatment also reduced the overall tumor burden in the group of patients (where in the carcinomas are removed upon diagnosis in most people).
Now the lead researcher Dr. Tang is continuing her focus on skin cancer prevention at Stanford. She's currently investigating whether it's possible to develop a topical formulation of the drug that can be applied directly to the skin to achieve a similar protective effect without associated cardiovascular risk. Hope she will get positive results via topical formulation .....
In my opinion its really a great achievement.We know that compounds with selective inhibitors of 5-LO (Lipoxygenase) and COX (Cyclooxegenase, that too COX-II) will be the best NSAIDs without any ulcerogenecity, its good see that the same compounds can be used to treat skin cancer....
Ref : http://med.stanford.edu/ism/2010/january/tang.html
Monday, December 14, 2009
Methotrexate & Ocrelizumab combination a new hope for RA patients....
About monoclonal antibodies :
Ref : http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=12487
Wednesday, December 2, 2009
CCII capsules offer safe and effective treatment for rheumatoid arthritis
More....CCII capsules offer safe and effective treatment for rheumatoid arthritis
Tuesday, October 6, 2009
Minocycline for stroke patients?
A recent study by the Dr. Cesar V. Borlongan (University of South Florida, USA) has lead to some interesting result, i.e., minocycline can be used to treat the stroke patients !. As per the claim by the researchers this drug might be a better option, when compared with the thrombolytic agent tPA (the only effective drug for acute ischemic stroke) and more over only 2 % of ischemic stroke patients benefit from this treatment due to its limited therapeutic window.
During a stroke, a clot prevents blood flow to parts of the brain, which can have wide ranging short-term and long-term implications. This study recorded the effect of intravenous minocycline in both isolated neurons and animal models after a stroke had been experimentally induced. At low doses it was found to have a neuroprotective effect on neurons by reducing apoptosis of neuronal cells and ameliorating behavioral deficits caused by stroke. The safety and therapeutic efficacy of low dose minocycline and its robust neuroprotective effects during acute ischemic stroke make it an appealing drug candidate for stroke therapy claims the researchers. Congrats for this interesting finding...
Ref : http://www.biomedcentral.com/1471-2202/10/126/abstract
Sunday, September 20, 2009
Podophyllotoxin in American Mayapple ?
Now the researchers from the US, found that mayapple colonies in the eastern part of the United States can be used for the development of high podophyllotoxin cultivars, which could subsequently provide the base for commercial production of podophyllotoxin in the United States.
Ref : http://hortsci.ashspublications.org/cgi/content/abstract/44/2/349
Sunday, June 28, 2009
Masitinib - a relief for arthritis patients ....
Sunday, April 19, 2009
Simponi the first biologic therapy to be approved for rheumatologic diseases !
Humira (brand name is an abbreviation of "Human Monoclonal Antibody in Rheumatoid Arthritis") is marketed in both preloaded 0.8 ml syringes and also in preloaded pen devices (called Humira Pen), both injected subcutaneously, typically by the patient at home. It cannot be administered orally, because the digestive system would destroy the drug. But its now the turn of Golimumab, a new fully human monoclonal antibody. Being a fully human MAb directed against TNF, Golimumab resembles Adalimumab (Humira, Abbott), which was the first such product to reach the market. Now the Canadian government has approved Golimumab along with ‘methotrexate’ for the treatment of three forms of Rheumatiod arthritis (Rheumatoid Arthritis, Ankylosing Spondylitis & Psoriatic Arthritis) and more over making this treatment the first biologic therapy to be approved.
With this approval in Canada, Simponi (Golimumb), in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms in adult patients with moderately to severely active RA; reducing signs and symptoms in adult patients with moderately to severely active PsA, alone or in combination with MTX; and reducing signs and symptoms in adult patients with active AS who have had an inadequate response to conventional therapies. More...
Sunday, February 1, 2009
Genetic basis of psoriasis revealed.....
This basic understanding of psoriasis is of significance becoz of the fact that, now one will be able target treatments to psoriasis patients based on the genetic alterations that have contributed to their disease. The two groups (Bowcock and her colleagues in Spain) found that the absence of two skin genes - LCE3B and LCE3C - increases the risk of psoriasis.
Both genes normally are activated after an injury to the skin. The researches suspect the absence of the genes could lead to an inappropriate immune response, which may cause the inflammation that is a hallmark of the disease. Until now, all of the genes linked to psoriasis have been involved in the immune system. But psoriasis is a disease of the immune system and the skin, and it makes sense that we would eventually find genes in the skin that are involved in the disease.
Though the new variants uncovered by the researchers each make only a small contribution to the overall genetic risk of the psoriasis, its a good beginning. This finding is important, because newly discovered variants have been associated with other inflammatory diseases such as Crohn's disease and autoimmune diseases like rheumatoid arthritis and lupus. Hope additional studies will help to tease apart the ways in which these diseases are connected at the level of DNA and this information will also aid in the search for more targeted drugs that can zero in on particular genetic defects that cause the diseases. More....
For Psoriasis picture, see the slide no., 4 of slide show of skin problems.